HB 1274 prohibits the delivery or distribution of abortion-inducing medicine, drugs, or substances into South Dakota for purposes of an illegal abortion, with exceptions for self-administration by a pregnant person, life-saving medical procedures, or miscarriage management. It establishes a Class 6 felony for violating this prohibition, imposes civil penalties up to $10,000 per dose, and allows civil lawsuits for wrongful death of an unborn child by specific parties (e.g., parents, the pregnant person, or their estate). The bill directly affects medical providers, pharmacies, and anyone transporting such substances into the state, while exempting individuals acting in self-defense or under medical necessity. The attorney general may seek injunctions to stop violations and collect civil penalties for deposit into a state fund.
HB 1257 redefines "abortion" in South Dakota law to include any action intending to terminate a pregnancy with knowledge it will likely cause the unborn child's death, while excluding specific medical treatments (like miscarriage care, ectopic pregnancy treatment, or procedures to save the unborn child's life). It requires physicians to determine that a pregnancy poses a "reasonably foreseeable risk of death" to the mother before permitting an abortion, mandates attempts to preserve both lives when possible, and mandates hospital-based reporting to the Department of Health. The bill directly affects pregnant individuals, physicians, and hospitals by setting strict medical criteria for legal abortions and prohibiting abortions based solely on psychological conditions or self-harm fears. It does not criminalize all abortions but creates a narrow exception for life-threatening conditions, with violations classified as Class 6 felonies.
HB 1099 would reclassify FDA-approved psilocybin medications from Schedule I to Schedule IV under South Dakota law. This change would allow medical providers to prescribe these specific pharmaceutical products without the strict restrictions currently applied to Schedule I substances. The bill specifically affects only psilocybin in drug products approved by the FDA, not raw psilocybin or unapproved formulations. This amendment aligns South Dakota's scheduling with federal approval status for medical use.
SB 220 directs South Dakota's Department of Corrections to conduct a study evaluating juvenile correctional and residential facilities. The study must examine best practices, therapeutic housing models, vocational training combined with mental health services, and staff-to-youth ratios, including inspections at three facilities outside South Dakota. The bill appropriates $50,000 from the general fund to cover study costs and requires a written report to the Legislative Research Council by September 1, 2026. This is a procedural study bill with no direct policy changes or new requirements for facilities, solely aimed at gathering information for future decisions.
HB 1210 bans employers, schools, state agencies, and other entities from requiring COVID-19 vaccinations as a condition for employment, enrollment, or accessing services. It directly affects workers, students, and individuals seeking public benefits or services. Violating this ban would result in a Class 2 misdemeanor penalty. The law overrides existing requirements and takes effect immediately upon enactment.
HB 1068 allows South Dakota pharmacists to dispense ivermectin and hydroxychloroquine to adults 18+ based on written protocols created by physicians. These protocols must include risk assessments, drug information (indications, usage, side effects), and instructions for handling adverse events. The law shields physicians and pharmacists from liability for good-faith compliance, except in cases of gross negligence or willful misconduct. It directly affects healthcare providers who dispense these drugs and patients receiving them under this new process.
HB 1112 modifies South Dakota's definition of "electronic smoking device" to explicitly include any device containing or delivering nicotine (or other substances with nicotine) intended for human consumption. This change clarifies that e-cigarettes, vape pens, e-cigars, and similar devices delivering nicotine fall under the definition, regardless of other substances they may contain. The amendment directly affects tobacco businesses selling these products and enforcement of existing laws regulating electronic smoking devices. The bill does not create new restrictions but ensures the definition aligns with how such devices are commonly used and marketed.
